- Apex Biotechnology
-
PerformanceThe company's stock price closed at NT$26.1 on the TSE on Wednesday, May 18, 2022.The company has reported consolidated revenues of NT$208 million for April 2022, representing a 18.8% increase on month and 32% increase on year.For the fourth quarter of 2021, the company totaled NT$561 million in consolidated revenues, up 10.2% sequentially and up 23.4% on year.Brief
Full name: Apex Biotechnology
Chinese name: 五鼎生物技術股份有限公司
Short name: Apex
Stock code: 1733
Tax ID: 16130182
Market: TSE
Established: 2 Dec 1997
Paid in capital: NT$997.27 million
Listed on TSE: 17 Sep 2001
Website: www.apexbio.com
-
-
Latest stock
Apex [1733] historical stock price (NT$) Date Volume (k) Transactions Value Open High Low Close Change Ask Bid 19-May 444 248 11,565,385 26.00 26.30 25.95 26.10 +0.00 +0.00% 26.05 26.10 18-May 462 272 12,141,581 26.20 26.60 26.10 26.10 +0.00 +0.00% 26.10 26.40 17-May 663 480 17,271,600 26.00 26.45 25.90 26.10 -0.05 -0.19% 26.10 26.15 16-May 1,235 872 32,148,346 26.60 26.60 25.70 26.15 +0.10 +0.38% 26.10 26.35 13-May 813 451 21,337,908 26.80 26.90 26.00 26.05 -0.25 -0.95% 26.05 26.15 - Source: TSE, compiled by Digitimes
Latest salesApex: Consolidated revenues, Apr 2021 - Apr 2022 (NT$m)
Month
Sales
M/M
Y/Y
YTD
Y/Y
Apr-22
208
18.8%
32%
730
(0.5%)
Mar-22
175
(5.6%)
0.1%
522
(9.4%)
Feb-22
186
15.3%
(11.7%)
347
(13.6%)
Jan-22
161
(18.8%)
(15.7%)
161
(15.7%)
Dec-21
198
0.1%
31.9%
2,132
6.3%
Nov-21
198
19.9%
38.5%
1,933
4.2%
Oct-21
165
(1.5%)
2.2%
1,735
1.4%
Sep-21
168
(1.2%)
11.7%
1,570
1.3%
Aug-21
170
(1.6%)
2.4%
1,403
0.2%
Jul-21
172
10.5%
(11.2%)
1,233
(0.2%)
Jun-21
156
(8.7%)
(30.6%)
1,061
1.9%
May-21
171
8.4%
(1.6%)
905
10.8%
Apr-21
158
(9.9%)
20.5%
734
14.2%
*Figures are consolidated
Source: TSE, compiled by Digitimes, May 2022Apex: Consolidated revenues, 4Q20 - 4Q21 (NT$m)
Quarter
Sales
Q/Q
Y/Y
YTD
Y/Y
4Q-21
561
10.2%
23.4%
2,132
6.3%
3Q-21
509
5.2%
(0%)
1,570
1.3%
2Q-21
484
(15.9%)
(8.4%)
1,061
1.9%
1Q-21
576
26.8%
12.6%
576
12.6%
4Q-20
455
(10.8%)
(31.8%)
2,005
(8.8%)
*Figures are consolidated
Source: TSE, compiled by Digitimes, May 2022Latest balance sheet and income statementApex: Consolidated balance sheet, 4Q20 - 4Q21 (NT$k)
Item
4Q-2021
3Q-2021
2Q-2021
1Q-2021
4Q-2020
Current assets
1,759,853
1,535,060
1,705,282
1,778,263
1,684,472
Intangible assets
106,478
112,051
115,088
123,172
128,920
Non-current assets
910,614
914,284
926,466
946,214
966,970
Assets
2,670,467
2,449,344
2,631,748
2,724,477
2,651,442
Current liabilities
785,888
657,086
796,465
923,643
883,426
Non-current liabilities
131,023
122,334
120,075
120,490
121,849
Liabilities
916,911
779,420
916,540
1,044,133
1,005,275
Stockholders' equity
1,753,556
1,669,924
1,715,208
1,680,344
1,646,167
*Figures are consolidated
Source: TSE, compiled by Digitimes, May 2022Apex: Consolidated income statement, 4Q20 - 4Q21 (NT$k)
Item
4Q-2021
3Q-2021
2Q-2021
1Q-2021
4Q-2020
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
NT$k
% of sales
Operating revenue
561,314
509,469
484,485
576,388
454,730
Gross profit (loss) from operations
145,514
25.9%
148,630
29.2%
126,900
26.2%
150,468
26.1%
106,827
23.5%
Operating expenses
97,290
17.3%
91,489
18%
89,586
18.5%
88,198
15.3%
80,320
17.7%
Operating income (loss)
48,224
8.6%
57,141
11.2%
37,314
7.7%
62,270
10.8%
26,507
5.8%
Non-operating expenses and losses
10,069
1.8%
3,832
0.8%
-12,177
-2.5%
-21,737
-3.8%
11,859
2.6%
Income from continuing operations before income tax
58,293
10.4%
60,973
12%
25,137
5.2%
40,533
7%
38,366
8.4%
Net income (loss)
81,534
14.5%
64,162
12.6%
22,528
4.6%
34,065
5.9%
33,054
7.3%
Diluted earnings per share (NT$)
0.8
0.6
0.2
0.3
0.3
*Figures are consolidated
Source: TSE, compiled by Digitimes, May 2022 - Apex Biotechnology full profile